Ibyra Olaparib 150mg Tablet

Ibyra Olaparib 150mg Tablet About

Ibyra Olaparib 150 mg Tablet is an oral anti-cancer medication containing Olaparib, a PARP (Poly ADP-ribose polymerase) inhibitor used in the treatment of certain types of cancers. It works by preventing cancer cells from repairing their damaged DNA, leading to cancer cell death while limiting harm to normal cells.

This medicine is primarily prescribed for patients with BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as maintenance therapy or in advanced stages, as recommended by an oncologist.

Key Features:

• Composition: Olaparib 150 mg

• Dosage Form: Tablet

• Therapeutic Class: Anti-cancer (PARP inhibitor)

• Route of Administration: Oral

• Prescription Required: Yes

Uses:

• Ovarian cancer

• Metastatic breast cancer

• Pancreatic cancer

• Prostate cancer (BRCA mutation-positive cases)

Mechanism of Action:

Olaparib inhibits PARP enzymes responsible for DNA repair in cancer cells. This leads to accumulation of DNA damage and ultimately results in the death of cancer cells, especially those with BRCA gene mutations.

Dosage & Administration:

• To be taken as prescribed by a qualified oncologist

• Tablets should be swallowed whole with water

• Do not crush, chew, or break the tablet

Possible Side Effects:

• Nausea and vomiting

• Fatigue

• Anemia

• Loss of appetite

• Diarrhea

• Headache

Storage Instructions:

• Store in a cool and dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

Safety Information:

• Use only under medical supervision

• Not recommended during pregnancy and breastfeeding

• Regular blood tests may be required during treatment

Targeted Oncology Therapy

Ibyra 150 is designed as an oral targeted therapy for specific types of cancer, particularly those associated with BRCA mutations. Its precision approach helps interrupt the growth of cancer cells by inhibiting an essential enzyme, making it highly effective in oncology treatment plans prescribed by specialists.


Safe Usage and Dosage

The usual strength of each tablet is 150 mg. Patients should take Ibyra 150 exactly as directed by their oncologist, typically with or without food. Always follow the prescribed schedule and never adjust dosage without medical advice, ensuring better outcomes and minimized side effects.


Storage and Handling

Keep Ibyra 150 Tablets stored at room temperature, away from moisture and direct heat. Check the packaging for both shelf life (generally 2-3 years from the date of manufacture) and details like color or shape as these may vary. Always keep this medication out of reach of children.